Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma. Issue 12 (16th September 2019)

• Record Type: Journal Article
• Authors: Uezono, Haruka; Indelicato, Daniel J.; Rotondo, Ronny L.; Sandler, Eric S.; Katzenstein, Howard M.; Dagan, Roi; Mendenhall, William M.; Mailhot Vega, Raymond; Brennan, Bernadette M.; Bradley, Julie A.
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 12(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-09-16
• Subjects: outcomes -- pediatric nasopharyngeal carcinoma -- proton therapy -- radiotherapy -- toxicity; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27990
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Purpose: In children treated for nasopharyngeal carcinoma, proton therapy and postchemotherapy target volumes can reduce the radiation dose to developing tissue in the brain and the skull base region. We analyzed outcomes in children with nasopharyngeal carcinoma treated with induction chemotherapy followed by moderate‐dose proton therapy. Methods/Materials: Seventeen patients with nonmetastatic nonkeratinizing undifferentiated/poorly differentiated nasopharyngeal carcinoma underwent double‐scattered proton therapy between 2011 and 2017. Median age was 15.3 years (range, 7‐21). The American Joint Committee on Cancer T and N stage distribution included the following: T1, one patient; T2, five patients; T3, two patients; and T4, nine patients; and N1, six patients; N2, nine patients; and N3, two patients. Median radiation dose to the primary target volume and enlarged lymph nodes was 61.2 Gy (range, 59.4‐61.2). Uninvolved cervical nodes received 45 Gy (range, 45‐46.8). All radiation was delivered at 1.8 Gy/fraction daily using sequential plans. In 11 patients, photon‐based intensity‐modulated radiotherapy was used for elective neck irradiation to optimize dose homogeneity and improve target conformity. All patients received induction chemotherapy; all but one received concurrent chemotherapy. Five received adjuvant beta‐interferon therapy. Results: Median follow‐up was 3.0 years (range, 1.6‐7.9). No patients were lost to follow‐up. Overall survival, progression‐free survival, and local control rates were 100%. Fifteen patients developed mucositis requiring enteral feeding (n = 14) or total parenteral nutrition (n = 1) during radiotherapy. Serious late side effects included cataract (n = 1), esophageal stenosis requiring dilation (n = 1), sensorineural hearing loss requiring aids (n = 1), and hormone deficiency (n = 5, including three with isolated hypothyroidism). Conclusion: Following induction chemotherapy, moderate‐dose proton therapy can potentially reduce toxicity in the brain and skull base region without compromising disease control. However, further follow‐up is needed to fully characterize and evaluate any reduction in long‐term complications.